SCHEMBL1815491

SCHEMBL1815491

OCC(O)Cc1cc(Cl)c2cccnc2c1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.46
MAPT P10636 7/20 0.42
HTT P42858 7/20 0.42
SMN1; SMN2 Q16637 7/20 0.42
ALDH1A1 P00352 6/20 0.42
LMNA P02545 6/20 0.42
ALOX12 P18054 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CCR6 P51684 1/20 0.42
CDK1 P06493 1/20 0.41
KDM4E B2RXH2 8/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
TDP1 Q9NUW8 4/20 0.40
TP53 P04637 2/20 0.40
MAPK1 P28482 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40
HSP90AA1 P07900 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12622768 0.88 HIF1A (0.46) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL3291657 0.86 GLRA1 (0.37) MAPTHTTSMN1; SMN2ALDH1A1LMNA
SCHEMBL12622766 0.83 HIF1A (0.44) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL12655272 0.82 KDM4E (0.45) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL4042845 0.81 HIF1A (0.48) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL3822384 0.79 HIF1A (0.64) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL1813245 0.79 EGLN1 (0.44) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL1811826 0.79 HIF1A (0.46) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL1811084 0.79 HIF1A (0.49) HIF1AMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL14033221 0.79 HIF1A (0.40) HIF1AMAPTHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
EP-2056823-A2 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF Wyeth (US) 2009-05-13 EP disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed
WO-2008024922-A2 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF WYETH (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 HIF1A 919/4885MAPT 2414/4885HTT 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.